NEW YORK (GenomeWeb News) – Natera today announced it has reached a deal with DiagCor to launch Natera's non-invasive prenatal screening test in Hong Kong.
DiagCor is based in Hong Kong and provides molecular diagnostic testing to doctors and healthcare professionals in the region.
The deal further expands the reach of Natera's test called Panorama into international markets and follows similar deals with the DASA Group and Hospital Israelita Albert Einstein to bring the test to Brazil, and with LifeLabs to make the Panorama available in Canada. In June Natera signed a distribution agreement with Unilabs covering Switzerland and Scandinavia.
Panorama uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Test Using SNPs to analyze the cell-free DNA from both the mother and the fetus.
Financial and other terms of today's deal were not disclosed.